Efficacy of paliperidone palmitate 3-month formulation in preventing hospital admissions. 60 months of follow-up
Introduction Paliperidone Palmitate 3-month formulation (PP3M) has shown a significantly longer time to relapse compared to placebo, with similar efficacy and safety to Paliperidone Palmitate 1-month (PP1M). However, studies of longer duration are required. Objectives The main objective of this st...
Main Authors: | S.L. Romero Guillena, B.O. Plasencia Garcia De Diego, F. Gotor Sanchez-Luengo |
---|---|
Format: | Article |
Language: | English |
Published: |
Cambridge University Press
2022-06-01
|
Series: | European Psychiatry |
Subjects: | |
Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822007301/type/journal_article |
Similar Items
-
Alternative initiation regimen of paliperidone palmitate long-acting injectable
by: I.E. Menendez Gil, et al.
Published: (2022-06-01) -
Cumulative Clinical Experience of the Use of Paliperidone Palmitate 3-Monthly Long-Acting Injection in the Treatment of Schizophrenia: A Critical Appraisal
by: García-Carmona JA, et al.
Published: (2023-09-01) -
Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
by: Giron‐Hernandez C, et al.
Published: (2023-04-01) -
Results from PSIPROSPER: A multicenter retrospective study to analyze the impact of treatment with paliperidone palmitate 1-month on clinical outcomes and hospital resource utilization in adult patients with schizophrenia in Portugal
by: João Marques-Teixeira, et al.
Published: (2022-11-01) -
Clinical relevance of Paliperidone Palmitate three-month intramuscular injection formulation: an Italian Real-World, Retrospective, one-year Mirror Image Study
by: S. Vanzetto, et al.
Published: (2022-06-01)